What is the average price target for CME GROUP INC (CME) stock?
20 analysts have analysed CME and the average price target is 308.13 USD. This implies a price decrease of -1.82% is expected in the next year compared to the current price of 313.83.
NASDAQ:CME • US12572Q1058
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CME GROUP INC (CME).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-04 | Argus Research | Downgrade | Buy -> Hold |
| 2026-02-05 | TD Cowen | Maintains | Buy -> Buy |
| 2026-02-05 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2026-02-05 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-05 | JP Morgan | Maintains | Underweight -> Underweight |
| 2026-02-05 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-01-15 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-01-14 | TD Cowen | Upgrade | Hold -> Buy |
| 2025-12-22 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-12-12 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-23 | UBS | Maintains | Neutral -> Neutral |
| 2025-10-23 | Deutsche Bank | Upgrade | Hold -> Buy |
| 2025-10-23 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-13 | Raymond James | Maintains | Outperform -> Outperform |
| 2025-10-08 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-01 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-25 | JP Morgan | Maintains | Underweight -> Underweight |
| 2025-09-25 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-09-08 | UBS | Maintains | Neutral -> Neutral |
| 2025-07-24 | UBS | Downgrade | Buy -> Neutral |
| 2025-07-24 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-07-24 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-07-10 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 10.854B 50.38% | 10.209B -5.94% | 12.257B 20.06% | 7.011B -42.80% | 7.381B 5.28% | 7.881B 6.77% | 7.946B 0.82% | 8.314B 4.63% | |
| EBITDA YoY % growth | 9.064B 62.52% | 8.347B -7.90% | 10.297B 23.35% | 5.013B -51.32% | 5.268B 5.09% | 5.869B 11.41% | 6.194B 5.54% | 6.512B 5.13% | |
| EBIT YoY % growth | 8.711B 67.06% | 8.011B -8.04% | 9.966B 24.41% | 4.594B -53.90% | 5.192B 13.02% | 5.569B 7.26% | 5.798B 4.11% | 6.059B 4.50% | |
| Operating Margin | 80.25% | 78.46% | 81.31% | 65.53% | 70.34% | 70.66% | 72.97% | 72.88% | |
| EPS YoY % growth | 9.34 17.04% | 10.26 9.85% | 11.21 9.26% | 12.05 7.52% | 12.82 6.37% | 13.94 8.70% | 14.72 5.61% | 14.23 -3.31% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 3.10 10.77% | 3.05 3.09% | 2.88 7.57% | 2.92 5.59% | 3.19 2.91% | 3.23 5.75% | 3.08 6.68% | 3.03 3.60% |
| Revenue Q2Q % growth | 1.761B 7.23% | 1.756B 3.78% | 1.691B 9.98% | 1.694B 2.75% | 1.815B 3.07% | 1.839B 4.73% | 1.764B 4.32% | 1.77B 4.49% |
| EBITDA Q2Q % growth | 1.28B -38.56% | 1.263B -55.11% | 1.21B -56.31% | 1.188B -62.01% | 1.288B 0.63% | 1.332B 5.46% | 1.317B 8.84% | 1.273B 7.15% |
| EBIT Q2Q % growth | 1.245B -37.77% | 1.231B -53.51% | 1.163B -53.87% | 1.158B -58.59% | 1.264B 1.53% | 1.306B 6.09% | 1.251B 7.57% | 1.222B 5.53% |
All data in USD
20 analysts have analysed CME and the average price target is 308.13 USD. This implies a price decrease of -1.82% is expected in the next year compared to the current price of 313.83.
CME GROUP INC (CME) will report earnings on 2026-04-21, before the market open.
The consensus EPS estimate for the next earnings of CME GROUP INC (CME) is 3.1 USD and the consensus revenue estimate is 1.76B USD.
The number of analysts covering CME GROUP INC (CME) is 20.